B-MS signs agreement for Ingenuity Systems software

Ingenuity Systems, a provider of information solutions for life science researchers, has entered into a multi-year agreement with US drug majorBristol-Myers Squibb for use of the Ingenuity Pathways Analysis software application.

The agreement provides enterprise-wide access to IPA for B-MS research scientists, who have access to the newest version of the system, which supports Affymetrix GeneChip Exon Arrays, many new species, and includes recent enhancements such as the Path Designer publishing tool and capabilities for metabolomics, biomarker, and toxicology research. The firm will use IPA for the interpretation, modeling and visualization of genomics and proteomics data to identify key biological insights to accelerate their drug discovery programs.

Sean Scott, senior vice president of Commercial Operations at Ingenuity Systems, said: "we are very pleased that B-MS has chosen Ingenuity as a partner for its drug discovery and development programs." He added that the drugmaker "has been a highly valued customer since 2004 and we regard their license renewal and multi-year commitment as confirmation that IPA is an integral part of their discovery programs."